Innovation Powers Us
Better Care Drives Us


Committed to Innovation
Dedicated to Improving Patients' Lives

MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, biotherapeutic solutions for tissue repair and regeneration.

Our strategy leverages our enzymatic technology platform, focusing on next-generation therapies for burn care, wound care and tissue repair.

NexoBrid, our commercial orphan biological product for eschar removal of severe thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours and does not harm surrounding viable tissue.

Nexobrid is FDA approved and currently marketed in the European Union as well as in other International markets such as India, Japan and Switzerland. It is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). It is due to begin US distribution in early 2023.

EscharEx, our next-generation bioactive topical therapy for debridement of chronic and hard-to-heal wounds is a product candidate in advanced stages of development. In two Phase 2 studies EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, with only a few daily applications.

MW005, our topical biological drug for the treatment of low risk Basal Cell Carcinoma (BCC), is a clinical-stage product candidate under development.

Our Culture

Our People. Our Values. Our Culture

  • We care
  • We innovate
  • We deliver
  • We learn
As a company, we are committed to the highest ethical principles and respect for the individual. We invest in our people, helping them develop, grow and appreciate the valuable resources they are.
We strive for technological and scientific leadership. We are dedicated to redefining the standard of care through our novel bio-therapeutics.
We place a high value on our customers and are focused on delivering patient satisfaction and better outcomes. We endeavor to be a reliable and agile partner that goes the extra mile to meet their customers’ needs, enabling them to achieve their goals.
As a learning organization, we continuously learn from those around us to improve ourselves. We seek to achieve leadership in everything we do, both as individuals and collectively as a company.
"At MediWound, our talented team of professionals transform great ideas into reality. Our goal is to elevate the standard of care for our patients, resulting in a much better quality of life"

Ofer Gonen | Chief Executive Officer

"I take enormous pleasure in knowing that my goal of making NexoBrid available to all patients has come to fruition, changing burn care for thousands of patients worldwide. For me, as a physician, to be able to leave this footprint in medicine is the greatest possible reward"

Professor Lior Rosenberg | Founder

The Total Solution

A Fully-Integrated Biopharmaceutical Company

MediWound has extensive history and experience developing, manufacturing, and commercializing non-surgical, regenerative solutions


In-house Expertise

  • In-vitro and In-vivo models
  • Analytical methods
  • Product formulation
  • Clinical development and data generation
  • Regulatory processes


State of the Art Facility

  • cGMP certified
  • Experienced team
  • Capable of aseptic processing for sterile products
  • Product Development manufacturing suites


Wide global network

  • Global expansion via strategic collaborations (Vericel, Kaken, BSV, GAG)
  • Supported by BARDA and DoD
  • EU direct sales force
  • Extensive worldwide supply chain

Our Team

Our People: Leading Change

  • Management
  • Board of Directors
  • Strategic Advisory Board

Ofer Gonen

Chief Executive Officer

Robert J. Snyder

Chief Medical Officer

Lior Rosenberg

Founder & Medical Director

Barry Wolfenson

EVP of Strategy and Corporate Development

Ety Klinger

Chief R&D Officer

Tzvi Palash

Chief Operating Officer

Boaz Gur-Lavie

Chief Financial Officer

Yaron Meyer

Executive Vice President & General Counsel

Alicia Torrenova

VP of European Operations

Andrey Kon

VP Plant Manager

Keren David-Zarbiv

VP Clinical Affairs

Roni Solomon

VP Finance

Eilon Asculai


Aya Ben-Yakov

Director of Regulatory Affairs

Nimrod Leuw

VP Quality

Nachum (Homi) Shamir

Chairman of the Board of Directors

Stephen T. Wills

Board Member

Vickie R Driver

Board Member

Sharon Kochan

Board Member

Nissim Mashiach

Board Member

Assaf Segal

Board Member

David Fox

Board Member

Sharon Malka

Board Member

Eric Shem-Tov

Co-founder and CEO of Equashield, a leading global provider of hazardous drug compounding technologies

Samuel Moed

Venture Partner at aMoon, Israel’s largest HealthTech VC fund

John C. Lantis

Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon


Patients' Stories and Physicians' Experience

Lee-Anne Jones

was treated witn NexoBrid

Prof. Dr. Jan Plock & Dr. Frank Sander

speak on their experince with NexoBrid


We are interested in motivated and talented scientists, clinicians and healthcare professionals that are seeking a dynamic, collaborative work environment.

Just us as we seek cure and advance care. Together we can improve patient outcomes and the standard of care.

    Click to delete